作者:Kevin Burgess、Javier Ibarzo、D. Scott Linthicum、David H. Russell、Hunwoo Shin、Aroonsiri Shitangkoon、Reiko Totani、Alex J. Zhang
DOI:10.1021/ja9631256
日期:1997.2.1
for removal of the N-phthaloyl group were to use 60% hydrazine in DMF for 1−3 h. Several sequences of amino acids coupled to ureas (“peptidic ureas”) and of sequential urea units (“oligoureas”) were prepared via solidphase syntheses and isolated by HPLC. Partition coefficients were measured for two of these peptidomimetics, and their water solubilities were found to be similar to the corresponding peptides
The present invention provides compounds that have antimalarial activity. More in particular, the present invention provides novel compounds that are analogues of pantothenamides. The pantothenamide analogues of this invention have particularly low IC50 values against the asexual blood stages and gametocytes of malaria parasites. Furthermore, the pantothenamide analogues of this invention are characterized by low hepatic metabolism. Therefore, pantothenamide analogues of the invention are particularly suitable for use in therapeutic and/or prophylactic treatment of protozoan infections in a human or animal subject in need thereof. The invention further provides pharmaceutical formulations comprising the pantothenamide analogues as well as the therapeutic and/or prophylactic uses of the pantothenamide analogues and pharmaceutical formulations comprising them.
Synthesis of imidacloprid derivatives with a chiral alkylated imidazolidine ring and evaluation of their insecticidal activity and affinity to the nicotinic acetylcholine receptor
imidazolidine ring were asymmetrically synthesized to evaluate their insecticidalactivity against adult female housefly, Musca domestica, and affinity to the nicotinicacetylcholinereceptor of the flies. The bulkier the alkyl group, the lower was the receptor affinity, but the derivatives methylated and ethylated at the R-5-position of the imidazolidine ring were equipotent to the unsubstituted compound. Quantitative
Asymmetric α-Hydroxylation of a Lactone with Vinylogous Pyridone by Using a Guanidine-Urea Bifunctional Organocatalyst: Catalytic Enantioselective Synthesis of a Key Intermediate for (20<i>S</i>)-Camptothecin Analogues
We have developed a catalytic asymmetricsynthesis of (S)‐4‐ethyl‐6,6‐(ethylenedioxy)‐7,8‐dihydro‐4‐hydroxy‐1H‐pyrano[3,4‐f]indolizine‐3,10(4H)dione (5 a), a synthetic intermediate for (20S)‐camptothecin analogues. A key step in this synthesis is an asymmetric α‐hydroxylation of a lactone with a vinylogous pyridone structure (8 a) by using a guanidine–urea bifunctional organocatalyst. The present oxidation
我们开发了(S)-4-乙基-6,6-(乙二氧基)-7,8-二氢-4-羟基-1 H-吡喃[3,4- f ]吲哚嗪-3,10的催化不对称合成(4 H)二酮(5 a),是(20 S)-喜树碱类似物的合成中间体。该合成的关键步骤是使用胍-脲双功能有机催化剂使具有乙烯基吡啶酮结构(8 a)的内酯不对称α-羟基化。本发明的氧化成功地应用于(+)的C20修饰的衍生物的合成- C20-desethylbenzylcamptothecin(13)。
Inhibitors of AKT Activity
申请人:Novartis AG
公开号:US20160287561A1
公开(公告)日:2016-10-06
Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.